Clarity

Clarity operates at the intersection of digital therapeutics, neurotechnology, medical devices, and virtual reality. Its differentiation is the attempt to use non-invasive multisensory stimulation—particularly synchronized light and sound at gamma frequencies—as a therapeutic intervention for neurodegenerative disease. That places the company closer to neuromodulation and clinical digital health than to conventional wellness applications or implant-based brain-computer-interface companies. The platform also emphasizes patient-specific protocols using neural data, biosensors, AI, and precision medicine, which could give it a more adaptable model than a fixed-content cognitive-training product if clinical evidence supports the approach. The company’s stated focus on Alzheimer’s and cognitive decline creates a large clinical need, but it also places Clarity in a demanding evidence and regulatory environment. Relative to pharmaceutical treatments, Clarity’s non-drug and non-implant approach is its main strategic distinction; relative to consumer VR products, its clinical-stage positioning and therapeutic device orientation are more central. The 2024 investor group, including Index Ventures and a16z Scout Fund, signals external interest but does not establish market leadership.

Clarity was founded on Jun 8, 2022 and appears to have moved through three recorded financing milestones: a pre-seed round on Dec 30, 2022, a seed round on Apr 15, 2024, and another seed round on Jun 1, 2026. The absence of disclosed amounts prevents measurement of capital velocity or financing scale, but the latest round and continued hiring suggest ongoing development rather than a dormant project. The company’s trajectory has expanded from a core multisensory stimulation device into a broader platform combining immersive technology, AI, biosensors, neural data, and precision medicine. Its product is described as a device delivering synchronized light and sound pulses intended to slow cognitive decline in neurodegenerative diseases. Hiring across virtual reality, neuroscience, brain-computer interfaces, and precision medicine points to an interdisciplinary buildout spanning hardware, clinical research, and software. A Mar 27, 2025 article focused on Alzheimer’s treatment through sensory stimulation provides evidence of increasing public visibility before the 2026 financing. Key uncertainties remain: clinical-stage status, undisclosed funding, no published valuation, and limited evidence in the profile about trial outcomes, regulatory milestones, commercial adoption, or product launch timing.